Rocket Pharmaceuticals, Inc.
RCKT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.71 | 0.98 | -0.28 | -1.28 |
| FCF Yield | -18.09% | -8.40% | -14.00% | -9.34% |
| EV / EBITDA | -4.26 | -10.51 | -5.69 | -7.24 |
| Quality | ||||
| ROIC | -55.45% | -49.62% | -42.85% | -34.95% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.81 | 0.79 | 0.80 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -1.99% | -13.19% | -44.91% | -24.28% |
| Safety | ||||
| Net Debt / EBITDA | 0.56 | 0.13 | 0.55 | 1.30 |
| Interest Coverage | -144.86 | -138.48 | -117.52 | -28.40 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -63.27 | 0.00 | 0.00 | 0.00 |